Atopic dermatitis case study

Atopic dermatitis (AD) is characterized by a complex pathophysiology with a wide spectrum of phenotypes. This high diversity makes mechanistic in silico approaches particularly adapted for guiding clinical development.

In the context of the bacterial lysate OM-85’s development to treat atopic dermatitis, [1] OM Pharma wanted to conduct an in silico exploration of the immune mechanisms driving the treatment response in order to characterize the best responders.

Nova has built a mechanistic model of AD representing the interplay between the skin barrier and the immune system in a pediatric population.



  1. The challenge
  2. The solution
  3. The outcome
  4. The references

case study

Get your questions answered by downloading the free pdf and learn more about our study!

  • Your information will be processed by Nova to send you the content requested. For more information about our processing or to exercise your GDPR rights, see our Privacy Policy
  • This field is for validation purposes and should be left unchanged.